News

ascopubs.org1mon
Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in ...
Conclusions: Preliminary clinical outcomes for the nilotinib-paclitaxel combination in patients with rare tumors showed encouraging signals of activity. To facilitate further evaluation of response ...
KTLA1mon
Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity
WESTON, Fla., May 27, 2025 /PRNewswire/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity.
Mena FN1mon
Apotex Launches Nilotinib Capsules, The First Generic Version Of Tasigna®(1) In The United States, With 180 Days Of Exclusivity - MENAFN.COM
WESTON, Fla., May 27, 2025 /PRNewswire/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the Uni Tuesday, 02 January 2024 12:17 GMT عربي ...
Monthly Prescribing Reference1mon
First Generic Version of Tasigna Now Available - MPR
Apotex’s nilotinib capsules are supplied in 3 dosage strengths: 50mg, 150mg, and 200mg. Each carton includes 4 blister packs containing 2 blister cards of 14 capsules each.
PharmiWeb1mon
Cell-Free Protein Synthesis - PharmiWeb.com
The Benefits of Cell-Free Protein Synthesis in Protein Production. The field of protein production is seeing widespread adoption of cell-free protein synthesis (CFPS), revolutionising the industry ...
C&EN2mon
Synthesis and Characterization of a BODIPY Conjugate of the BCR-ABL Kinase Inhibitor Tasigna (Nilotinib): Evidence for Transport of Tasigna and Its Fluorescent Derivative by ...
Tasigna (Nilotinib) is a BCR-ABL kinase inhibitor recently approved by the Food and Drug Administration, which is indicated for the treatment of drug-resistant chronic myelogenous leukemia (CML). The ...